Xeris Biopharma (NASDAQ:XERS) Insider Sells $133,494.66 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the completion of the sale, the insider owned 1,144,462 shares in the company, valued at $9,167,140.62. The trade was a 1.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $133,827.98.
• On Monday, June 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.06, for a total value of $101,002.02.

Xeris Biopharma Trading Down 9.2%

Xeris Biopharma stock opened at $7.36 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of 122.67 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The stock’s 50 day simple moving average is $7.64 and its two-hundred day simple moving average is $6.79. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG raised its position in Xeris Biopharma by 682.4% during the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares during the period. Vanguard Group Inc. lifted its holdings in Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares in the last quarter. Qube Research & Technologies Ltd grew its position in shares of Xeris Biopharma by 67.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after purchasing an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Granahan Investment Management LLC increased its stake in shares of Xeris Biopharma by 249.4% during the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after purchasing an additional 873,236 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.